Get the Stockscreener App
107.00
2.35%
-2.46
After Hours:
107.01
0.01
+0.01%
Jazz Pharmaceuticals Plc stock is traded at $107.00, with a volume of 606.79K.
It is down -2.35% in the last 24 hours and down -5.31% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$109.46
Open:
$109.41
24h Volume:
606.79K
Relative Volume:
0.47
Market Cap:
$6.59B
Revenue:
$3.99B
Net Income/Loss:
$463.16M
P/E Ratio:
15.07
EPS:
7.1
Net Cash Flow:
$1.10B
1W Performance:
-1.27%
1M Performance:
-5.31%
6M Performance:
-12.84%
1Y Performance:
+1.74%
1-Day Range:
$106.69
$109.60
1-Week Range:
$106.01
$110.80
52-Week Range:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
107.00 | 6.84B | 3.99B | 463.16M | 1.10B | 7.10 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.28 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 41.82M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.43 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Deutsche Bank AG - Defense World
Cetera Investment Advisers Buys New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Idiopathic Hypersomnia Treatment Market: Drug Pipeline, - openPR.com
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - Yahoo Finance
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences - Citizen Tribune
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Leadership to Present Strategic Updates at Two Major Healthcare Conferences in June - Stock Titan
Psychedelic Drugs Market Opportunities in the United States - openPR.com
Jazz Pharmaceuticals: One Step Forward, One Back (NASDAQ:JAZZ) - Seeking Alpha
Transcript : Jazz Pharmaceuticals plc Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Cut by Cubist Systematic Strategies LLC - Defense World
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook - Yahoo Finance
Mercer Global Advisors Inc. ADV Has $202,000 Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Jazz outlines $4.15B-$4.4B revenue target for 2025 amid growth in neuroscience portfolio and new oncology approvals - MSN
Weekly Investment Analysts’ Ratings Updates for Jazz Pharmaceuticals (JAZZ) - Defense World
July 18th Options Now Available For Jazz Pharmaceuticals - Nasdaq
Jazz Pharma stock falls after lowered full year guidance - MSN
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings May Just Be The Starting Point - Yahoo Finance
Jazz Pharmaceuticals (NASDAQ:JAZZ) Cut to “Hold” at StockNews.com - Defense World
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance - ADVFN
Jazz Pharmaceuticals at Bank of America 2025: Strategic Growth Amid Challenges - Investing.com Nigeria
Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers - Yahoo Finance
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Avadel Pharma gains after appeals court ruling in Lumryz case with Jazz Pharma - MSN
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update - Yahoo Finance
Hikma $50M Deal to Settle Xyrem Antitrust Claims - USA Herald
Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts - simplywall.st
Jazz Pharmaceuticals plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
Royal Bank of Canada Has Lowered Expectations for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - Defense World
StockNews.com Downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Buy - Defense World
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2025 Earnings Call Transcript - Insider Monkey
Hikma Cuts $50M Deal To End Antitrust Claims In Xyrem MDL - Law360
Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case - Reuters
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook - MSN
After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Vera Therapeutics (VERA) and Dexcom (DXCM) - The Globe and Mail
Jazz Earnings: Strong Demand for Epidiolex and Xywav Drive Growth; Shares Very Undervalued - Morningstar
Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Gap Down After Earnings Miss - Defense World
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Decoding Jazz Pharmaceuticals PLC (JAZZ): A Strategic SWOT Insig - GuruFocus
Jazz Pharmaceuticals (JAZZ) Rating Maintained Despite Price Target Cut | JAZZ Stock News - GuruFocus
RBC Capital Maintains Outperform Rating on Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (JAZZ): Morgan Stanley Adjusts Price Target - GuruFocus
Jazz Pharmaceuticals (JAZZ) Target Price Lowered by Piper Sandler | JAZZ Stock News - GuruFocus
RBC Capital Adjusts Price Target for Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (JAZZ) Price Target Reduced by Morgan Stanl - GuruFocus
Jazz Pharmaceuticals (JAZZ) Maintains Strong Momentum with 'Buy' Rating | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (JAZZ): Among Billionaire Ray Dalio’s Bridgewater’s Stock Picks with Huge Upside Potential - Insider Monkey
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Jazz Pharmaceuticals Plc Stock (JAZZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mulligan Seamus | Director |
May 12 '25 |
Buy |
103.00 |
1,621 |
166,962 |
101,621 |
| COZADD BRUCE C | Chairman & CEO |
May 01 '25 |
Sale |
116.35 |
1,000 |
116,350 |
439,307 |
| COZADD BRUCE C | Chairman & CEO |
May 02 '25 |
Sale |
120.00 |
500 |
60,000 |
438,807 |
9.13%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):